For the past several years, the addition of trastuzumab to chemotherapy has become the standard of care for patients with metastatic, HER2-positive breast cancer; the results of several large, adjuvant trials also support its use in the adjuvant setting. Currently, clinical trials evaluating the ...
The influence of BRCA mutations in Her2-positive disease, Her2 mutations, and the impact of miRNA is vague to date. Antibody-drug conjugates (ADC) such as T-DM have been established as important treatment strategies, especially in Her2-positive disease. Key Message: However, up-to-date ...
milestones, and a review of HER2-positive breast cancer. Detailed clinical profiles of select drugs of interest can be found in the separate Dashboard report. Clinical, regulatory, and other updates will be made to the Dashboard on a monthly basis. ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
Adjuvant Therapy for HER2-Positive Breast Cancer Anita Slomski, MA JAMA. 2019;322(12):1134. doi:10.1001/jama.2019.14757 Full Text Patients with small, human epidermal growth factor receptor 2 (HER2)–positive breast tumors treated with adjuvant paclitaxel and trastuzumab showed persistently ...
LEARNING OBJECTIVES Apply available research evidence to individualize the selection and use of adjuvant systemic therapy for patients with HER2-positive localized breast cancer who have previously received neoadjuvant treatment. Evaluate published research data to guide the selection and duration of adjuvant...
Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis and poor outcomes of several types of cancer, including advanced gastric an
HER2 POSITIVE BREAST CANCER - BIOLOGY AND RESISTANCE doi:10.1016/S0960-9776(19)30635-6Breast, TheFrédérique Penault-Llorca
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal
This program is currently inactive. In the meantime, please visit Genentech Patient Support Services to learn about the resources available for individuals prescribed Genentech medicines. Our programs are designed to assist you based on your specific needs and situation....